Large fraction irradiation with or without XXXX in advanced non-oat cell @entity2 : a phase III randomized trial of the RTOG. Radiation Therapy Oncology Group.

@entity1 @entity137 @entity8712 @entity66 @entity5 @entity2 @entity519 @entity2359
The Radiation Therapy Oncology Group (RTOG) investigated the use of @entity8712 as an @entity519 cell sensitizer in a Phase III prospective randomized trial employing radiotherapy, 600 cGy twice weekly to a total of 3600 cGy with and without @entity8712 in the treatment of locally advanced non-metastatic squamous cell, adeno, or large cell @entity2 . Between January 1980 and July 1983, 117 @entity1 from 21 institutions were enrolled. One-hundred eight @entity1 were evaluable; 53 in the combined treatment arm and 55 in the radiation alone arm. Grade 3 or worse complications associated with radiation occurred in 17% of @entity1 . Esophageal @entity137 accounted for the majority of complications. Two (4%) @entity1 in the radiotherapy plus @entity8712 group experienced grade 3 peripheral @entity2359 . Complete or partial responses were produced in 58% of the @entity1 with radiotherapy alone and 36% of those treated with radiotherapy plus @entity8712 (p = 0.08). At the time of first progression, over 50% of the @entity1 had persistent @entity66 . Median survival was 7 months regardless of treatment. @entity8712 in the dose and schedule employed did not enhance the effect of radiotherapy on either @entity5 control or overall survival in @entity1 with advanced @entity2 .
